Medical Kickback (Rebate) Lawyer
Medical Kickback (Rebate) Lawyer | Understanding the Criminal and Administrative Exposure Together
A "kickback" (rebate) case in the medical field refers to money, goods, entertainment, or other economic benefits given by a pharmaceutical company, medical device company, or similar entity to a doctor, dentist, veterinarian, or medical institution in exchange for prescribing or using their products (약사법, 의료법). These cases are unusual in Korean criminal practice because a single set of facts can trigger a criminal prosecution and, separately, an administrative sanction such as license suspension or revocation, cancellation of designation as a health insurance provider, or exclusion from public bidding. Because the criminal case and the administrative case are decided by different authorities using different standards, a defense strategy that only addresses one track often fails to protect the client's livelihood. This page walks through both tracks and the issues that most often decide how a case turns out.
Medical Kickback (Rebate) | What Counts as an Illegal Rebate Under Korean Law
Kickback liability in Korea is not a single crime but a patchwork of provisions across several statutes, each targeting a different actor or industry. Understanding which provision applies to your situation determines both the potential penalty and the available defenses.
The Medical Service Act prohibits doctors, dentists, and medical institutions from receiving money or other economic benefits from a drug or device manufacturer, wholesaler, or importer in connection with prescribing or using their products (의료법 제23조의5). Violation can lead to criminal punishment as well as suspension of the medical license or the institution's operation. The key factual issue is usually whether the benefit received was genuinely tied to promoting sales, or was a legitimate payment such as a lecture fee or research grant.
The Pharmaceutical Affairs Act prohibits pharmaceutical companies, wholesalers, and their employees from offering economic benefits to medical institutions, pharmacists, or medical personnel to induce the sale or use of drugs (약사법 제47조 제2항). Companies frequently structure these payments as sponsorships, samples, or market research fees, and the disputed question is often whether the arrangement falls within the narrow list of exceptions set by the Ministry of Health and Welfare's fair trade rules for the industry.
Where the recipient is an employee of a private hospital corporation acting on behalf of the institution, prosecutors sometimes add a charge of taking a bribe in breach of trust (형법 제357조) alongside the Medical Service Act charge. This can increase both the range of potential sentence and the scope of assets subject to forfeiture, so whether this additional charge is properly applied is a point worth scrutinizing early.
A rebate conviction often triggers a separate review of whether the underlying prescriptions or treatments were medically unnecessary, which can lead to demands for repayment of national health insurance benefits and additional administrative fines. This financial exposure is frequently larger than the criminal fine itself and needs to be addressed as part of the overall defense plan.
Administrative Sanctions Run on a Separate Timeline
Even where a criminal case ends in a fine or a suspended sentence, the health authority can still impose an independent administrative sanction, such as suspension of a medical license for a set number of months or cancellation of a pharmaceutical distributor's permit. These proceedings use a lower burden of proof than a criminal trial and are frequently decided before the criminal case is finalized, so waiting for the criminal outcome before responding to an administrative notice can foreclose options.
Medical Kickback (Rebate) | What Kinds of Payments Actually Count as a Rebate
Not every benefit exchanged between a pharmaceutical company and a doctor is illegal. The line between a legitimate business expense and an illegal rebate is drawn by a limited set of exceptions, and most disputes come down to whether a specific payment fits inside one of them.
The narrow list of permitted exceptions
The Ministry of Health and Welfare's fair trade rules for the pharmaceutical and device industry list specific permitted categories such as product samples within set limits, reasonable compensation for genuine clinical trials, and support for attending academic conferences. If a payment does not fit squarely within one of these categories, it is treated as a rebate regardless of what label the parties gave it (약사법 제47조 제2항).
Disguised forms: consulting fees, market research, sponsorship
Investigators frequently focus on payments labeled as lecture fees, consulting fees, or market research fees that have no real underlying service, or where the fee is disproportionate to the work actually performed. Whether documentation exists showing genuine work product is often decisive in these cases.
Cash versus in-kind benefits
The prohibition covers not just direct cash payments but also in-kind benefits such as free equipment, travel, entertainment, and even excessive gifts, so the absence of a cash transfer does not by itself avoid liability.
Medical Kickback (Rebate) | How the Criminal Case and the Administrative Sanction Interact
One of the most misunderstood aspects of rebate cases is that resolving the criminal charge does not resolve the administrative sanction, and the two proceedings can produce inconsistent outcomes because they are decided by different bodies applying different standards of proof.
Different standards of proof
A criminal conviction requires proof beyond a reasonable doubt, while an administrative sanction such as license suspension is typically decided on a lower administrative evidentiary standard. This means it is possible to avoid criminal conviction yet still receive a license suspension based on the same underlying facts.
Timing and notice deadlines for administrative sanctions
Once the health authority issues a prior notice of an intended sanction, there is usually a short statutory window to submit a written opinion or request a hearing before the sanction becomes final. Missing this window can mean losing the chance to contest the sanction even if the criminal case is still ongoing, so administrative deadlines should be tracked independently of the criminal case schedule.
Self-reporting and leniency considerations
In some rebate investigations, particularly those involving pharmaceutical companies with multiple recipients, self-reporting or cooperating with the investigation before formal charges can affect both the level of criminal sentence sought and the severity of the accompanying administrative sanction, though the effect varies case by case and is not guaranteed.
⚠ Watch the Administrative Response Deadline
The opportunity to submit an opinion or request a hearing before an administrative sanction becomes final is time-limited and separate from any deadline in the criminal case. Confirm the exact deadline stated on the notice you received rather than assuming it aligns with the criminal proceeding.
Medical Kickback (Rebate) | Points That Commonly Decide the Outcome
Because rebate cases usually rest on documentary and transactional evidence rather than eyewitness testimony, the defense typically focuses on characterizing the transaction rather than disputing that a payment occurred.
Characterizing the payment as a legitimate exception
Where records exist showing a genuine clinical trial, a real lecture, or a bona fide research collaboration, arguing that the payment falls within a recognized exception is often the central line of defense, supported by contemporaneous documentation rather than after-the-fact explanation.
Scale and repetition affecting sentencing
Courts and administrative authorities generally treat a single, isolated payment differently from a systematic scheme involving multiple recipients or repeated transactions over time, so the scope of the investigation and how the total amount is calculated is frequently contested.
Corporate liability alongside individual liability
Where the giver is a company, prosecutors may also examine whether the company itself, and not just the individual employee, should face liability or a separate administrative penalty, which raises internal compliance and delegation-of-authority issues that need to be reviewed separately from the individual's defense.
Medical Kickback (Rebate) | From Initial Contact to Resolution
Review the investigation notice, any seized documents, and the specific transactions at issue to identify which statute applies and whether an administrative sanction notice has also been issued or is likely.
Prepare for police questioning, including organizing documentation that supports characterizing disputed payments as legitimate exceptions where applicable.
If a prior notice of administrative sanction is received, submit a written opinion or request a hearing within the statutory deadline, independent of how the criminal case is progressing.
Respond to the prosecutor's charging decision, and if charges are filed, prepare a trial or summary proceeding defense addressing both the facts of the transaction and applicable sentencing factors.
After the criminal case concludes, confirm whether any related health insurance repayment demand or administrative sanction remains open, since these can continue even after a criminal case is closed.
Medical Kickback (Rebate) | How Fees Are Generally Set
Typically set based on the stage of the case (investigation-only versus indictment and trial), the number of statutes and transactions involved, and whether a parallel administrative sanction response is also being handled.
If used, this is generally tied to a defined outcome such as a non-indictment decision, a reduced charge, or a favorable administrative sanction result, and should be agreed in writing before representation begins.
Because responding to a license suspension or similar administrative sanction is a separate proceeding from the criminal case, it is often billed separately, reflecting the additional filings and hearing preparation involved.
Covers costs such as document review of large transaction records, expert review of accounting or clinical trial documentation, and travel for hearings outside Seoul.
※ Costs vary depending on case complexity and specific circumstances; exact fees will be provided during consultation. No specific outcome is guaranteed.
Medical Kickback (Rebate) | Self-Check Before Your Consultation
1️⃣ For Doctors and Medical Institutions
- Have you received a formal notice of investigation or a request to appear for questioning?
- Do you have documentation showing the disputed payment was for a genuine clinical trial, lecture, or research collaboration?
- Have you also received a prior notice of administrative sanction from the health authority regarding your license?
- Is a national health insurance repayment review also underway alongside the criminal investigation?
2️⃣ For Pharmaceutical and Device Company Employees
- Was the payment structured through an internal compliance approval process, and can you produce those records?
- Are multiple employees or multiple recipient institutions involved in the same investigation?
- Could the company itself face a separate administrative penalty or exclusion from public bidding?
- Have you been asked to cooperate or provide a statement about colleagues, and have you discussed the implications with counsel first?
3️⃣ Administrative Sanction Response
- What is the exact deadline stated on the prior notice for submitting an opinion or requesting a hearing?
- Have you gathered evidence showing mitigating circumstances, such as the isolated nature of the incident?
- Do you understand whether the administrative sanction can proceed regardless of the outcome of the criminal case?
4️⃣ Financial Exposure Beyond the Criminal Fine
- Have you calculated the potential scope of any health insurance repayment demand?
- Could a license suspension affect ongoing contracts, employment, or hospital operation permits?
- Is there a risk of asset forfeiture if a breach-of-trust bribery charge is also being pursued?
